 Home > Active Ingredient News > Blood System > 2023CASH| Talk about the precise diagnosis and innovative treatment of MDS/MPN

2023CASH| Talk about the precise diagnosis and innovative treatment of MDS/MPN

 Last Update: 2023-02-02
 Source: Internet
 Author: User

Tags

cell tak

advantages fuel cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

With the gradual seriousness of China's aging society, the incidence of myelodysplastic syndrome (MDS) and myeloproliferative tumor (MPN), the most common myeloid neoplastic diseases in elderly patients, has increased year by year, increasing the huge medical burden
for patients, their families and the country.
In terms of diagnosis, with the development and wide application of next-generation sequencing (NGS) technology, accurate diagnosis, molecular typing and molecular prognosis evaluation
of MDS and MPN have been realized.
However, in terms of treatment, MDS and MPN have encountered bottlenecks in innovative treatment compared with the explosive development of new treatment strategies for lymphatic tumors and acute myeloid leukemia
.
At the 3rd Hematology Development Conference - MDS/MPN Thematic Forum held on the afternoon of January 7, domestic and foreign experts conducted extensive and in-depth discussions
on the accurate diagnosis and innovative treatment of MDS/MPN.
The MDS/MPN sub-forum was co-chaired by Professor Raajit Rampal, Executive Director of Leukemia Center of Sloan Kettering Cancer Center, Professor Liu Qiqi, Dean of the Institute of Hematology, Southern Medical University, and Professor Xiao Zhijian, Deputy Dean of the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences
).
At the beginning of the conference, Professor Wu Depei, Chairman of the Hematology Branch of the Chinese Medical Association, congratulated
the convening of the academic conference of the forum.
Subsequently, Professor Raajit Rampal, on behalf of the presidium of the forum, introduced the main contents of this academic report and expressed his gratitude
to the experts and colleagues who participated in the conference.

CASH

Sub-forum academic report

Professor Rafael Bejar

The era of molecular typing of the blood system has arrived, and understanding and applying the current classification and diagnosis standards is the key to
achieving accurate diagnosis and individualized treatment of MDS/MPN 。 Professor Rafael Bejar of the Morse Cancer Center at the University of California, San Diego, USA, made a report entitled "The Updated Classifation of MDS and Related Disorders", detailing the changes in disease naming, diagnostic criteria and subgroup classification of MDS, MPN and MDS/MPN parts of the new WHO classification of classification and the story behind the changes.
In particular, the reform of molecular typing diagnosis has brought unprecedented development opportunities
for new treatments and personalized treatments for MDS/MPN.
In the report, Professor Rafael Bejar specifically commented and affirmed the recent verification of the diagnostic criteria for MDS typing in the 5th edition of WHO and the new ICC criteria based on single-center large samples published by Professor Xiao Zhijian's team from the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) in Leukemia and the British Journal of Haematology.
The importance of international cooperation in improving the deficiencies in existing standards was emphasized
.

Professor Omar Abdel-Wahab

In addition to hematopoietic stem cell transplantation, the field of MDS treatment still lacks therapeutic drugs and means
that can be definitive.
On the basis of molecular typing diagnosis, how to achieve targeted therapy for various subtypes of MDS is the key to the future MDS treatment field
.
Professor Omar Abdel-Wahab's team at Sloan Kettering Cancer Center has long focused on the molecular mechanism of splicing factor mutations in myeloid tumors and the development of new therapeutic strategies
.
Professor Omar Abdel-Wahab presented a presentation entitled "Understanding & Targeting Altered RNA Splicing in Leukemia", presenting his team's latest research results: creatively establishing a new gene therapy method for myeloid tumors with spliceoster mutations , that is, by introducing synthetic mutant splice-specific recognized introns to induce the expression of cytotoxic proteins and kill cells with splice mutations without harming cells
not accompanied by splice mutations.
In addition, the BCL-2 inhibitor Venotoclax was also found to have a synergistic antitumor effect
with down-regulating certain spliceogen kinases.
CLK/DYRK kinase inhibitors can exert antileukemia effects by mediating abnormal splicing of key factors that regulate leukemia cell growth, which may help treat
Venotoclax-resistant leukemia.

Professor Raajit Rampal

Professor Raajit Rampal of Sloan Kettering Cancer Center introduced and compared the clinical research results mainly for MPN secondary leukemia in recent years, as well as some innovative preclinical research results, and shared the clinical path
of Sloan Kettering Cancer Center MPN team in the treatment of MPN secondary leukemia.

Professor Li Bing

Professor Li Bing, Hospital of Hematology, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), gave a report
entitled "Challenges in the Treatment of PMF by JAK Inhibitors".
He pointed out that in the past five years, with the increasing application of JAK inhibitor Ruxolitinib in medium- and high-risk PMF patients in China, a series of problems have been put in front of
Chinese hematologists.
Realizing and focusing on solving these problems will help Chinese hematologists better apply JAK inhibitors and develop new diagnosis and treatment strategies to achieve precise treatment
of PMF.

Professor Wang Yu

Professor Wang Yu of Peking University People's Hospital made a report entitled "Progress of Hematopoietic Stem Cell Transplantation of MDS", which reported in detail the indications and donor selection, pretreatment system optimization and selection, and prevention and treatment of recurrence in hematopoietic stem cell transplantation of MDS patients in recent years, especially shared the relevant experience of the transplant team of Peking University People's Hospital, and put forward some ideas
on how to accurately transplant in the future.

Finally, Professor Liu Qiqi, chair of the sub-forum, presided over the discussion session, and Professor Xiao Zhijian, Professor Liu Qiqi, Professor Chang Chunkang, Professor Chen Suning, Professor Tong Hongyan, Professor Du Xin and Professor Wang Yu had an in-depth and extensive discussion
。 It was agreed that research on the clinical and molecular characteristics of domestic multi-center MDS/MPN based on the 5th edition of the WHO typing diagnostic criteria should be carried out as soon as possible under the framework of the MDS/MPN collaborative group, and the pathogenesis of MDS/MPN at the molecular level and innovative treatment strategies based on molecular mechanisms should be explored in depth from the actual clinical problems, and a higher standard of MDS/MPN diagnosis and treatment guidelines in China should be formulated to provide more patients with more accurate diagnosis and treatment plans
.

Source: Institute of Hematology, Hematology Hospital